XORTX Therapeutics Nears Key Regulatory Submission Following Share Consolidation

XORTX completes 1-for-5 reverse stock split for Nasdaq compliance as its lead gout drug, XRx-026, prepares for New Drug Application submission.

XORTX Therapeutics Inc. has successfully executed a reverse stock split, a strategic move viewed as strengthening its position for a Nasdaq listing. The company is simultaneously advancing its lead drug candidate toward a critical regulatory milestone, signaling a pivotal phase in its development.

Lead Drug Candidate Approaches Regulatory Filing

The primary focus for XORTX remains its flagship program, XRx-026, a treatment for gout. The company is in the final preparatory stages before submitting a formal New Drug Application (NDA) to regulators. This development targets a significant unmet medical need, as many patients do not respond adequately to existing gout therapies. The company's scientific approach centers on inhibiting the xanthine oxidase enzyme to reduce uric acid production, a mechanism foundational to its broader pipeline of kidney-focused therapies.

Beyond XRx-026, XORTX is developing several other specialized therapeutic programs:
* XRx-008: A treatment for autosomal dominant polycystic kidney disease (ADPKD).
* XRx-101: A therapy for acute kidney and organ injury resulting from viral respiratory infections.
* XRx-225: A preclinical program for type 2 diabetic nephropathy (T2DN).

Share Consolidation Completed

Effective Monday, April 6, 2026, the company implemented a 1-for-5 share consolidation. The necessary approvals for this corporate action were secured from both the TSX Venture Exchange and the Nasdaq Stock Exchange. Such consolidations are commonly utilized to adjust a company's share price into a range that meets the continued listing requirements of major exchanges.

Upcoming Catalysts and Strategic Path

The anticipated NDA submission for XRx-026 represents the most significant near-term catalyst for XORTX. Market observers are closely monitoring the company's progress toward this and subsequent regulatory milestones in the gout treatment landscape. The completion of the share consolidation is seen as a procedural step that aligns the company's structure with its strategic objective of maintaining a strong presence on a leading U.S. exchange as it progresses its clinical programs.